Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models

Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models

Although T cell-recruiting CD3-binding bispecific antibodies (BiMAb) have been proven to be clinically effective for hematologic malignancies, the success of BiMAb targeting solid tumor-associated antigens (TAA) in carcinomas so far remains poor. We reasoned that provision of co-stimulatory BiMAb in...

Full description

Bibliographic Details
Main Authors: Karsten M. Warwas, Marten Meyer, Márcia Gonçalves, Gerhard Moldenhauer, Nadja Bulbuc, Susanne Knabe, Claudia Luckner-Minden, Claudia Ziegelmeier, Claus Peter Heussel, Inka Zörnig, Dirk Jäger, Frank Momburg
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Immunology
Subjects:
T cells
co-stimulation
tumor cell spheroids
tumor therapy
cytotoxicity
bispecific antibodies
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.719116/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.719116/full

Similar Items